CVS Health Corporation (CVS) Fair Value & Analysis
Healthcare · US · Market cap $133B
CVS Health Corporation
CVS · US
Fair value as of: Aug 13, 2026
From 26 valuation models · updated today
Fair value updated Aug 13, 2026, revised from $42.54 to $42.25 (−0.7%) since Jul 12, 2026. Share price −10.5% over the past month.
A solid business, but screening 56% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($70.87). The favourable scenario is already priced in.
- The model range is unusually wide ($22.86 to $70.87). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $41.28 – $110.60 · fair‑value band $22.86 – $70.87 · the $94.99 price screens above the $42.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
CVS Health Corporation (CVS) currently trades at $94.99, while our model-based Fair Value estimate is $42.25, implying the stock looks roughly 55.5% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, CVS Health Corporation generated revenue of $406B at a net margin of 0.7%. Revenue grew 6.1% year over year. It earns a return on equity of 3.8%. Net debt stands at $85.1B. Fundamentals as of Aug 13, 2026
Our scenario range runs from $22.86 (bear case) to $70.87 (bull case); at $94.99, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 3% below its 52-week high and 66% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at -56%, CVS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth DCF ($88.76) versus Earnings-Based ($15.87). Highest evidence: Growth DCF (80).
Notify me when CVS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 76
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments.
Full company description
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CVS Health Corporation reported revenue of $402B in FY2025 versus $292B in FY2021, a compound +8.3%/yr. Reported net income was $1.8B in FY2025, compounding −31.4%/yr from FY2021.
of which total revenue +10.3 pp · buybacks/dilution −1.5 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
CVS screens 56% overvalued. Compare with UnitedHealth Group →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Can CVS Sustain Its 2026 Recovery After Raising Earnings Guidance?
- How CVS Is Building on Its Consumer-Health Care Technology Push
- Mark Cuban says your 401(k) is ‘part of the cost of health care problem.’ Do you dump Big Insurance and own your values?
- CVS Health (CVS) Rolls Out New PBM Tools As Employer Trust Grows
Peer Group
Healthcare Plans · 15 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Healthcare Plans median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| UnitedHealth Group UNH | $405.59 | $292.06 | -28% |
| Elevance Health, Inc ELV | $399.14 | $426.53 | +7% |
| The Cigna Group CI | $277.41 | $495.42 | +79% |
| Humana Inc HUM | $388.83 | $126.42 | -67% |
| Centene Corporation CNC | $67.07 | $111.96 | +67% |
| Molina Healthcare, Inc MOH | $206.06 | $199.31 | -3% |
| Oscar Health, Inc OSCR | $29.61 | $59.22 | +100% |
| Alignment Healthcare, Inc ALHC | $13.52 | $2.37 | -82% |
| Progyny, Inc PGNY | $25.42 | $16.44 | -35% |
| Bradsaúde S.A SAUD3 | R$13.88 | R$17.73 | +28% |
Compare CVS Health Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CVS Health Corporation (CVS) overvalued or undervalued?
What is the fair value of CVS?
What is the quality score of CVS?
What is the revenue of CVS Health Corporation (CVS)?
What is the net profit margin of CVS?
Does CVS Health Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track CVS Health Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.